ライフサイエンスコーパス: Plasmodium falciparum malaria

1 shmania major (cutaneous leishmaniasis), and Plasmodium falciparum (malaria).

2 eases and obesity, is associated with severe Plasmodium falciparum malaria.

3 gans plays a key role in the pathogenesis of Plasmodium falciparum malaria.

4 on genetics simulators cannot suitably model Plasmodium falciparum malaria.

5 tment in pregnancy (IPTp) is used to prevent Plasmodium falciparum malaria.

6 development of an effective vaccine against Plasmodium falciparum malaria.

7 rison to results of PCR for the detection of Plasmodium falciparum malaria.

8 hain, protects West African children against Plasmodium falciparum malaria.

9 more effective liver-stage vaccines against Plasmodium falciparum malaria.

10 ed-species infections protect against severe Plasmodium falciparum malaria.

11 (AMA-1) is a promising vaccine candidate for Plasmodium falciparum malaria.

12 NF) has been linked with the pathogenesis of Plasmodium falciparum malaria.

13 tistage, multigene DNA-based vaccine against Plasmodium falciparum malaria.

14 sfunction are common complications of severe Plasmodium falciparum malaria.

15 ntly needed to stem the global resurgence of Plasmodium falciparum malaria.

16 with hemoglobin variants in areas of endemic Plasmodium falciparum malaria.

17 n life as a "natural vaccine" against severe Plasmodium falciparum malaria.

18 malaria, especially of chloroquine-resistant Plasmodium falciparum malaria.

19 therapy (ACT) is the first-line treatment of Plasmodium falciparum malaria.

20 could be considered for rescue treatment for Plasmodium falciparum malaria.

21 could be considered for rescue treatment for Plasmodium falciparum malaria.

22 t on ART, all of whom required treatment for Plasmodium falciparum malaria.

23 otect children from severe and uncomplicated Plasmodium falciparum malaria.

24 bstantial reduction in deaths resulting from Plasmodium falciparum malaria.

25 most efficacious treatment of uncomplicated Plasmodium falciparum malaria.

26 w era in effectively treating drug-resistant Plasmodium falciparum malaria.

27 ine treatment against confirmed or suspected Plasmodium falciparum malaria.

28 ered as a means to interrupt transmission of Plasmodium falciparum malaria.

29 es a serious threat to the global control of Plasmodium falciparum malaria.

30 d of care for the treatment of uncomplicated Plasmodium falciparum malaria.

31 transmission-blocking vaccines (TBV) against Plasmodium falciparum malaria.

32 dothelium are central to the pathogenesis of Plasmodium falciparum malaria.

33 859 patients aged 6 months to 12 years with Plasmodium falciparum malaria.

34 trophil function in 58 Gambian children with Plasmodium falciparum malaria [55 (95%) with uncomplicat

35 te in Mozambican children with uncomplicated Plasmodium falciparum malaria 7 days after combination t

36 The evolution of resistance in Plasmodium falciparum malaria against most available tre

37 A total of 248 cases of severe Plasmodium falciparum malaria among children aged 3 mont

38 Plasmodium falciparum malaria, an infectious disease cau

39 se-control study of 996 children with severe Plasmodium falciparum malaria and 1220 community control

40 ignificant protection against infection with Plasmodium falciparum malaria and also against clinical

41 Coinfection with Plasmodium falciparum malaria and Epstein-Barr virus (EB

42 plasma samples from patients with confirmed Plasmodium falciparum malaria and in human whole-blood s

43 The contemporary spatial limits of Plasmodium falciparum malaria and its endemicity within

44 one that is widely used to prevent and clear Plasmodium falciparum malaria and Pneumocystis jirovecii

45 In vitro growth of Toxoplasma gondii, Plasmodium falciparum (malaria) and Cryptosporidium parv

46 ratory distress (238 with pneumonia, 41 with Plasmodium falciparum malaria, and 14 with both).

47 disease, previous history of preterm birth, Plasmodium falciparum malaria, and any helmintic infecti

48 stance is a major obstacle to the control of Plasmodium falciparum malaria, and its origins and modes

49 blood mononuclear cells) to the liver-stage Plasmodium falciparum malaria antigen ME-TRAP.

50 le cell traits confer protection from severe Plasmodium falciparum malaria are not yet fully elucidat

51 e public health and economic consequences of Plasmodium falciparum malaria are once again regarded as

52 Protective antibodies in Plasmodium falciparum malaria are only acquired after ye

53 Characteristic features of Plasmodium falciparum malaria are polyclonal B cell acti

54 , BinaxNOW initially misclassified a case of Plasmodium falciparum malaria as non-falciparum.

55 1 (AMA1) is a leading vaccine candidate for Plasmodium falciparum malaria, as antibodies against rec

56 group has relatively better protection from Plasmodium falciparum malaria, as reflected by fewer sym

57 breast milk correlated with mothers who had Plasmodium falciparum malaria at delivery.

58 nce of the spatiotemporal prevalence of both Plasmodium falciparum malaria-attributable and non-malar

59 ay of the current treatment of uncomplicated Plasmodium falciparum malaria, but ACT resistance is spr

60 Artesunate is a vital therapy for Plasmodium falciparum malaria, but artesunate tablets ha

61 ne treatment recommended by the WHO to treat Plasmodium falciparum malaria, but clinical resistance a

62 ait (HbAS) is known to be protective against Plasmodium falciparum malaria, but it is unclear when du

63 ncy is believed to confer protection against Plasmodium falciparum malaria, but the precise nature of

64 howed modest efficacy of the vaccine against Plasmodium falciparum malaria, but was not powered to as

65 le-cell trait) or HbC (HbAC) protect against Plasmodium falciparum malaria by unclear mechanisms.

66 data remain too weak to accurately enumerate Plasmodium falciparum malaria cases.

67 icant peaks in 2010; examples were increased Plasmodium falciparum malaria (chi(2)=37.57, p<0.001); i

68 bC) are well known to protect against severe Plasmodium falciparum malaria, conclusive evidence on th

69 Plasmodium falciparum malaria detected at delivery in pe

70 In Plasmodium falciparum malaria, determination of which ce

71 land, Oreg.), to detect Plasmodium vivax and Plasmodium falciparum malaria during an outbreak in Hond

72 PM increases MMc and that MMc alters risk of Plasmodium falciparum malaria during infancy.

73 In Plasmodium falciparum malaria, erythrocyte invasion by c

74 Severe Plasmodium falciparum malaria evolves through the interp

75 Chloroquine (CQ)-resistant Plasmodium falciparum malaria has been a global health c

76 The spread of drug-resistant Plasmodium falciparum malaria has been a major impedimen

77 ntury, successful antifolate therapy against Plasmodium falciparum malaria has been attributed to hos

78 Plasmodium falciparum malaria has been found to blunt er

79 Vaccine development in human Plasmodium falciparum malaria has been hampered by the e

80 in regulating host immunity in children with Plasmodium falciparum malaria has not previously been re

81 ens may be able to confer protection against Plasmodium falciparum malaria; however, a technology for

82 Plasmodium falciparum malaria importation from Africa to

83 n dengue hemorrhagic fever in Bangkok and of Plasmodium falciparum malaria in a highland area of west

84 al involving 210 children with uncomplicated Plasmodium falciparum malaria in Blantyre, Malawi.

85 nation therapy (ACT) for multidrug-resistant Plasmodium falciparum malaria in Cambodia because of few

86 a urine malaria test (UMT) for diagnosis of Plasmodium falciparum malaria in febrile patients.

87 r prime-boost vaccination approaches against Plasmodium falciparum malaria in humans.

88 attributed to the resistance it provides to Plasmodium falciparum malaria in its heterozygous state,

89 ed individuals with concomitant asymptomatic Plasmodium falciparum malaria in Mali.

90 Congenital Plasmodium falciparum malaria in newborns is uncommon in

91 and HbAC are hypothesized to protect against Plasmodium falciparum malaria in part by enhancing natur

92 s the first-line treatment for uncomplicated Plasmodium falciparum malaria in response to failing SP

93 ual spraying and other interventions against Plasmodium falciparum malaria in seasonal settings in Af

94 misinin, has been described in patients with Plasmodium falciparum malaria in southeast Asia.

95 he recent emergence of artemisinin-resistant Plasmodium falciparum malaria in western Cambodia could

96 able malaria transmission, susceptibility to Plasmodium falciparum malaria increases during first pre

97 As the prevalence of artemisinin-resistant Plasmodium falciparum malaria increases in the Greater M

98 nstrate this with four examples: identifying Plasmodium falciparum malaria-infected erythrocytes in a

99 ia (CM) is a severe clinical complication of Plasmodium falciparum malaria infection and is character

100 Plasmodium falciparum malaria infection is associated wi

101 e most effective treatment for uncomplicated Plasmodium falciparum malaria infection.

102 During Plasmodium falciparum malaria infections, von Willebrand

103 Plasmodium falciparum malaria is a deadly infectious dis

104 Plasmodium falciparum malaria is a major cause of death

105 Severe Plasmodium falciparum malaria is a major cause of death

106 Chloroquine-resistant Plasmodium falciparum malaria is a major health problem,

107 Fatal Plasmodium falciparum malaria is accompanied by systemic

108 Plasmodium falciparum malaria is an important cause of m

109 Much of the virulence of Plasmodium falciparum malaria is caused by cytoadherence

110 Cerebral Plasmodium falciparum malaria is characterized by adhesi

111 Plasmodium falciparum malaria is characterized by the po

112 a disease is important for understanding how Plasmodium falciparum malaria is controlled.

113 Although the burden of Plasmodium falciparum malaria is gradually declining in

114 Plasmodium falciparum malaria is increasingly difficult

115 Antigenic variation in Plasmodium falciparum malaria is mediated by transcripti

116 Immunity to Plasmodium falciparum malaria is naturally acquired in i

117 and vaccine-induced immunity to blood-stage Plasmodium falciparum malaria is of long-standing intere

118 Mass drug administration for elimination of Plasmodium falciparum malaria is recommended by WHO in s

119 The development of clinical immunity to Plasmodium falciparum malaria is thought to require year

120 lability and accuracy of our software on 245 Plasmodium falciparum malaria isolates from three contin

121 uitoes, the world's most important vector of Plasmodium falciparum malaria, locate their human hosts

122 dren, aged 3 months to 14 years, with severe Plasmodium falciparum malaria matched to uncomplicated m

123 emisinin-based combination therapy (ACT) for Plasmodium falciparum malaria may be threatened by paras

124 Life-threatening diseases, such as Plasmodium falciparum malaria, melioidosis, and African

125 Plasmodium falciparum malaria originated in Africa and b

126 Genome analysis of the Plasmodium falciparum malaria parasite already is identi

127 Each Plasmodium falciparum malaria parasite carries about 50

128 -specific system of genetic integration into Plasmodium falciparum malaria parasite chromosomes.

129 independent host-parasite interaction in the Plasmodium falciparum malaria parasite invasion of RBCs.

130 e pathology associated with infection by the Plasmodium falciparum malaria parasite.

131 stereomers 5a and 5c showed activity against Plasmodium falciparum malaria parasites (IC50 approximat

132 Plasmodium falciparum malaria parasites carry approximat

133 Plasmodium falciparum malaria parasites export the prote

134 opy to investigate structural development of Plasmodium falciparum malaria parasites in normal and ge

135 It is unknown whether the presence of Plasmodium falciparum malaria parasites in umbilical cor

136 Plasmodium falciparum malaria parasites invade and remod

137 Antigenic variation in Plasmodium falciparum malaria parasites results from swi

138 Here we show that erythrocyte-stage Plasmodium falciparum malaria parasites spontaneously ta

139 Increasing resistance of Plasmodium falciparum malaria parasites to chloroquine a

140 of a cell-free lysate prepared from asexual Plasmodium falciparum malaria parasites to remove uracil

141 Plasmodium falciparum malaria parasites were transformed

142 high antimalarial potencies in vitro against Plasmodium falciparum malaria parasites, and furans 5a a

143 and evaluate their resistance to invasion by Plasmodium falciparum malaria parasites.

144 ein, fatty acids, anionic phospholipids, and Plasmodium falciparum malaria parasitized erythrocytes.

145 Severe anemia is a lethal complication of Plasmodium falciparum malaria, particularly in children.

146 t surface antigens play an important role in Plasmodium falciparum malaria pathogenesis and in immune

147 uinone that is used therapeutically to treat Plasmodium falciparum malaria, Pneumocystis carinii pneu

148 ne that is used therapeutically for treating Plasmodium falciparum malaria, Pneumocystis jirovecii pn

149 Plasmodium falciparum malaria remains a devastating publ

150 Plasmodium falciparum malaria remains a global public he

151 Severe Plasmodium falciparum malaria remains a leading cause of

152 Plasmodium falciparum malaria remains a leading cause of

153 Plasmodium falciparum malaria remains a major cause of i

154 Plasmodium falciparum malaria remains a major public hea

155 Plasmodium falciparum malaria remains one of the world's

156 The pathogenesis of coma in severe Plasmodium falciparum malaria remains poorly understood.

157 f adjunct or anti-disease therapy for severe Plasmodium falciparum malaria requires cellular and mole

158 Chloroquine resistance in Plasmodium falciparum malaria results from mutations in

159 Naturally acquired protective immunity to Plasmodium falciparum malaria takes years to develop.

160 primary marker of artemisinin resistance in Plasmodium falciparum malaria that threatens the long-te

161 Plasmodium falciparum malaria, the most lethal form of h

162 ut on 279 children with severe anemia due to Plasmodium falciparum malaria; the results were similar

163 n G6PD deficiency and severe and complicated Plasmodium falciparum malaria through a case-control stu

164 Emergence of CQ drug-resistant Plasmodium falciparum malaria throughout endemic areas o

165 a mathematical model of the transmission of Plasmodium falciparum malaria to explore the potential e

166 ation therapy, might prevent transmission of Plasmodium falciparum malaria to mosquitoes.

167 ng progress has been seen with reductions in Plasmodium falciparum malaria transmission in some parts

168 a were analyzed with network analysis tools, Plasmodium falciparum malaria transmission maps, and glo

169 Anopheles gambiae mosquitoes that transmit Plasmodium falciparum malaria use a series of olfactory

170 es gambiae mosquito, which is the vector for Plasmodium falciparum malaria, uses a series of olfactor

171 The development of an efficacious Plasmodium falciparum malaria vaccine remains a top prio

172 T molecular marker for chloroquine-resistant Plasmodium falciparum malaria was retrospectively measur

173 Adult patients (n = 28) with severe Plasmodium falciparum malaria were enrolled in a prospec

174 Adults with Plasmodium falciparum malaria were randomized to receive

175 erapy on transmission, Gambian children with Plasmodium falciparum malaria were treated with standard

176 f uncomplicated malaria, and 687 episodes of Plasmodium falciparum malaria were treated with study dr

177 A total of 577 episodes of uncomplicated Plasmodium falciparum malaria were treated with study dr

178 A subunit vaccine for Plasmodium falciparum malaria will need to contain well-

179 predict which of the children infected with Plasmodium falciparum malaria will progress to CM.

180 , 48, and 72 hours) in African children with Plasmodium falciparum malaria with a prespecified delta

181 years, who were treated for 249 episodes of Plasmodium falciparum malaria with artemether-lumefantri

182 causal (ie, pre-erythrocytic) prophylaxis of Plasmodium falciparum malaria with prolonged activity wo

183 the influence of climate on the incidence of Plasmodium falciparum malaria worldwide and how it might

184 dely-recommended treatment for uncomplicated Plasmodium falciparum malaria worldwide.